MedTrace Logo

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

NCT02982486 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether nivolumab plus ipilimumab are effective and safe in the treatment of sarcoma and endometrial carcinoma patients with somatic deficient MMR as a selection tool.

Conditions

  • Soft Tissue Sarcoma
  • Bone Sarcoma
  • Chondrosarcoma
  • Gastrointestinal Stromal Sarcoma
  • Ewing's Tumor Metastatic
  • Ewing's Tumor Recurrent
  • Osteosarcoma
  • Desmoplastic Small Round Cell Tumor

Interventions

DRUG

Ipilimumab

Ipilimumab 1 mg/kg every 6 weeks

DRUG

Nivolumab

Ninolumab 240 mg IV every 2 weeks

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Daniela Katz, M.D · Assaf-Harofeh Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2020-06-30
Completion
2020-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02982486 on ClinicalTrials.gov